Caitlin Costello

Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    Harvard University2002Cum Laude
    2004Robert J. Fahey Award for Compassion in Doctoring
    2006Worth F Bloom Award for High Standard of Excellence and Level of Compassion
    2010  - 2012Akliviadis Vasiliadis Fellowship Award for Clinical Research
    2011American Society of Hematology Abstract Achievement Award
    2012American Society of Clinical Oncology Travel Award

    Collapse Overview 
    Collapse overview
    Research Interests
    As a member of the Division of Blood and Marrow Transplantation, Dr Costello is dedicated to providing excellent care for patients with a variety of hematologic malignancies, with a specific focus in lymphoproliferative disorders and bone marrow transplantation. Dr Costello’s research interests focus particularly on the refinement of the management and treatment of multiple myeloma. She is dedicated to conducting clinical trials with novel agents and treatment strategies to expand the therapeutic options for patients with multiple myeloma. As we enter the age of personalized medicine, Dr. Costello is principally interested in developing treatment strategies that are specific to the most finite genetic and molecular details of each individual patient’s disease.

    Education and Training
    BA - Biology, Harvard University, Cambridge, MA - 2002
    MD - Medicine, Tufts University, School of Medicine, Boston, MA - 2006
    Internship/Residency - Internal Medicine, New York Presbyterial/Weill Cornell Medical Center, New York, NY - 2006-2009
    Fellowship - Hematology/Oncology, University of California, San Diego, CA - 2009-2012

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience. Biomedicines. 2024 Dec 27; 13(1). Trando A, Ghamsari F, Yeung P, Costello C, Saunders I, Jeong AR. PMID: 39857619; PMCID: PMC11759176.
      View in: PubMed   Mentions:
    2. A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature. Br J Haematol. 2024 Jul; 205(1):364-367. Wang HY, Louis HMS, Costello CL, Murray SS, Dell'Aquila ML. PMID: 38735761.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future Oncol. 2024 Jan; 20(3):131-143. Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, Lee HC, Stokes M, Ren K, Stull DM, Cherepanov D, Bogard K, Noga SJ, Girnius S. PMID: 37807952.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576. Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. PMID: 37783970; PMCID: PMC10579053.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    5. Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience. Am J Transplant. 2023 02; 23(2):291-293. Brubaker AL, Urey MA, Taj R, Parekh JR, Berumen J, Kearns M, Shah M, Khan A, Kono Y, Ajmera V, Barman P, Tran H, Adler ED, Silva Enciso J, Asimakopoulos F, Costello C, Bower R, Sanchez R, Pretorius V, Schnickel GT. PMID: 36804136.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    6. Newly diagnosed multiple myeloma: making sense of the menu. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):539-550. Costello CL. PMID: 36485145; PMCID: PMC9820388.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2023 03; 23(3):e171-e181. Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hájek R, Cook G, Abonour R, Armour M, Morgan KE, Yeh SP, Costello CL, Berdeja JG, Davies FE, Zonder JA, Lee HC, Omel J, Spencer A, Terpos E, Hungria VTM, Puig N, Fu C, Ferrari RH, Ren K, Stull DM, Chari A. PMID: 36641358.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    8. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells. STAR Protoc. 2021 06 18; 2(2):100565. Vora AA, Mondala PK, Costello C, MacLeod AR, Crews LA. PMID: 34136833; PMCID: PMC8176358.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    9. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens. Transfusion. 2021 07; 61(7):2054-2063. Phou S, Costello C, Kopko PM, Allen ES. PMID: 33960433.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    10. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Jul; 17(19):2499-2512. Hájek R, Minarík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Barinová M, Kuhn M, Šilar J, Cápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. PMID: 33769076.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    11. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 02 18; 11(2):40. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. PMID: 33602913; PMCID: PMC7891472.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    12. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell. 2021 04 01; 28(4):623-636.e9. Mondala PK, Vora AA, Zhou T, Lazzari E, Ladel L, Luo X, Kim Y, Costello C, MacLeod AR, Jamieson CHM, Crews LA. PMID: 33476575; PMCID: PMC8026723.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    13. Supportive Care in Multiple Myeloma. Curr Hematol Malig Rep. 2020 04; 15(2):56-61. Guzdar A, Costello C. PMID: 32172361.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    14. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression. Proc Natl Acad Sci U S A. 2019 12 03; 116(49):24881-24891. Banerjee S, Wei T, Wang J, Lee JJ, Gutierrez HL, Chapman O, Wiley SE, Mayfield JE, Tandon V, Juarez EF, Chavez L, Liang R, Sah RL, Costello C, Mesirov JP, de la Vega L, Cooper KL, Dixon JE, Xiao J, Lei X. PMID: 31754034; PMCID: PMC6900511.
      View in: PubMed   Mentions: 27     Fields:    
    15. The future of checkpoint inhibition in multiple myeloma? Lancet Haematol. 2019 09; 6(9):e439-e440. Costello C. PMID: 31327688.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019 May; 15(13):1411-1428. Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V. PMID: 30816809; PMCID: PMC6854441.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    17. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol. 2018 03; 180(6):821-830. Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R. PMID: 29435979; PMCID: PMC5873373.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    18. Therapy sequencing strategies in multiple myeloma: who, what and why? Future Oncol. 2018 01; 14(2):95-99. Costello C, Mikhael JR. PMID: 29219615.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat Commun. 2017 12 04; 8(1):1922. Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson CHM. PMID: 29203771; PMCID: PMC5715072.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    20. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041; PMCID: PMC5495179.
      View in: PubMed   Mentions: 15     Fields:    
    21. An update on the role of daratumumab in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jan; 8(1):28-37. Costello C. PMID: 28042457; PMCID: PMC5167079.
      View in: PubMed   Mentions: 15  
    22. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ, Leukemia and Lymphoma Society Blood Cancer Research Partnership. PMID: 27410923; PMCID: PMC5149459.
      View in: PubMed   Mentions: 290     Fields:    Translation:HumansCellsCTClinical Trials
    23. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R, National Comprehensive Cancer Network. PMID: 26553768; PMCID: PMC4891187.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    24. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Feb; 18(2):257-64. Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED. PMID: 21736867.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    Caitlin's Networks
    Concepts (123)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California